Seattle Genetics is a rapidly growing company that is making the Seattle area a hotbed for Cancer Research set to attract a lot of cancer patients to the region. The future seems bright based on the company’s plans. They are expanding the distribution of their cancer drug and plan on introducing more drugs in the future. That shows that there is need for the company’s drug in the market and a huge chance of expansion and profitability. Seattle Genetics also plans to increase the size of its staff to handle the increase in production. Plans are to hire about 100 more employees who will increase their human resource base.
The company is undoubtedly very ambitious. It intends to be the leading cancer research center in the country, a fact supported by its plans. The firm has only one drug being sold commercially. Its name is Adcetris. It is predominantly used to cure lymphomas. Seattle Genetics wants to expand the diseases which the drug can cure, and a lot of research is being directed that way at the company. Adcetris has over 200 million dollars in annual sales in the US and Canada alone. Much more is sold outside North America by its partner firm, Takeda Pharmaceuticals.
The company has gone on from the success of their first drug to develop twelve more drugs. Though unfinished, they offer bright prospects for the company’s future. One of its new drugs known as 33A is being developed to cure acute lymphoid leukemia, one of the most prevalent forms of the disease.
Seattle Genetics is a company that functions on a long-term mentality. The company already has 800 employees but plan to hire much more with the continued success of their cancer medication. The incredible growth rate of the company can be seconded by the fact that the firm has been hiring roughly 100 people each year for the past half-decade. Most of the newly hired employees will not be in the research department but the operations of the company. Seattle Genetic’s CEO and Founder, Clay Siegall says Seattle Genetics has room for plenty of more employees.